Related Experiment Video
Updated: Dec 8, 2025

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
Anti-drug Antibodies Monitoring in Biologics Use: Clinical Implications
Rim Dhahri1, Selma Athimni1, Maroua Slouma1
1Rheumatology Department, Military Hospital of Tunis, Tunis, Tunisia.
Background:
Over the years, drug monitoring-such as Anti-Drug Antibodies (ADA) dosage- has witnessed major transformations. In fact, ADA are more and more used in rheumatology and gastro-enterology in monitoring chronic inflammatory disease therapeutic response. The main purpose of those researches is to produce less immunogenic drugs and, in consequences, to improve tolerance and efficiency since immunogenicity of those drugs still is the main constraint to their long-term use. The aim of this review was to highlight anti-drug-antibodies potential effects on the pharmacokinetics and bioavailability of biotherapies as well as their clinical implications.
Methods:
For this purpose, we collected and summarized published data on PubMed using keywords "Biologics, Rheumatoid Arthritis, Spondyloarthritis, Crohn disease, Anti-drug antibodies, residual rate, immunogenicity, efficacy, tolerance". The time-period selected for this study was 2000-2019.
Results:
Anti-Drug-antibodies decrease the pharmaco-availability of drugs and, in consequences, its efficiency and high risk of refractory diseases and side effects.
Conclusion:
Recent literature is consistent with the fact that drug monitoring using ADA dosage coupled with residual drug concentration offers reliable options to comfort practitioner' therapeutic management decisions. This is particularly interesting in failure of treatment or in side effects onset situations.
More Related Videos
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring: Overview and Classification
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

